IgA nephritis, a leading cause of primary glomerulonephritis, frequently recurs after kidney transplantation, posing a significant challenge to long-term graft survival. Clinicians face a particular dilemma when managing older transplant recipients, a population often excluded from pivotal trials, leaving treatment decisions to extrapolation and clinical judgment.
This gap in evidence means that the efficacy and safety profiles of established and emerging therapies in this vulnerable cohort are not fully understood, complicating efforts to balance immunosuppression with the risks of infection and malignancy.
IgA nephritis, also known as Berger's disease, represents the most common primary glomerulonephritis worldwide, characterised by IgA immune complex deposition in the glomerular mesangium. Its clinical course is highly variable, ranging from asymptomatic microscopic haematuria to rapidly progressive glomerulonephritis. A significant proportion of patients, up to 40% in some cohorts, progress to end-stage kidney disease (ESKD) within 10 to 20 years, necessitating kidney replacement therapy, often transplantation.1
Recurrence of IgA nephritis in the allograft is a well-recognised complication, occurring in 20% to 60% of transplanted patients, depending on the diagnostic criteria and follow-up duration. This recurrence is a major contributor to late graft loss. The pathophysiology involves a complex interplay of genetic predisposition, mucosal immune dysregulation, and environmental factors, leading to the production of aberrantly glycosylated IgA1, which forms immune complexes that deposit in the kidney. The standard immunosuppressive regimens used to prevent transplant rejection do not reliably prevent IgA nephritis recurrence, highlighting the need for targeted therapies.1
The Uncharted Territory of Older Patients
Older patients, generally defined as those over 65 years of age, constitute a growing proportion of individuals undergoing kidney transplantation. This demographic shift reflects advancements in surgical techniques, immunosuppressive regimens, and a broader acceptance of older recipients. However, these patients often present with a higher burden of comorbidities, including cardiovascular disease, diabetes, and malignancy, which significantly influence their tolerance to immunosuppression and their overall prognosis. Their immune systems also exhibit immunosenescence, leading to altered responses to infection and vaccination, and potentially different responses to immunosuppressive agents.2
Despite their increasing numbers, older transplant recipients are consistently underrepresented in clinical trials for IgA nephritis, both in native kidneys and in recurrent disease post-transplant. This exclusion stems from concerns about increased adverse event rates, polypharmacy, and the complexity of managing multiple comorbidities. As a result, treatment decisions for recurrent IgA nephritis in this population are largely based on data extrapolated from younger cohorts, or from studies in native kidney disease, which may not accurately reflect the unique physiological and immunological context of an older, immunosuppressed patient with a transplanted kidney.2
Current Approaches and Their Limitations
Management strategies for recurrent IgA nephritis post-transplant typically mirror those for native IgA nephritis, focusing on reducing proteinuria and inflammation. Renin-angiotensin system (RAS) blockade with ACE inhibitors or ARBs is a cornerstone therapy, aiming to reduce intraglomerular pressure and proteinuria. Corticosteroids, often in combination with other immunosuppressants like mycophenolate mofetil (MMF) or calcineurin inhibitors (CNIs), are also used, particularly for more aggressive forms of recurrence characterised by rapidly declining graft function or significant proteinuria.3
But the application of these therapies in older transplant recipients carries distinct risks. Corticosteroids, while effective anti-inflammatory agents, are associated with a higher incidence of diabetes, osteoporosis, cataracts, and infections in older individuals. MMF can cause gastrointestinal side effects and myelosuppression, which may be less tolerated in an elderly patient with reduced physiological reserve. CNIs, such as tacrolimus and cyclosporine, are nephrotoxic and can exacerbate pre-existing hypertension and dyslipidaemia, conditions prevalent in older transplant recipients. The delicate balance between preventing graft loss from IgA nephritis recurrence and avoiding severe adverse events is particularly challenging in this demographic.3
The Diagnostic Conundrum
Diagnosing recurrent IgA nephritis in the allograft requires a biopsy, which carries inherent risks, especially in older patients who may have increased fragility or comorbidities that complicate invasive procedures. The histological features of recurrent IgA nephritis can also overlap with other causes of graft dysfunction, such as chronic antibody-mediated rejection or CNI toxicity, making definitive diagnosis challenging. Furthermore, the clinical presentation of recurrence can be subtle, often manifesting as slowly progressive proteinuria or microscopic haematuria, which may be overlooked or attributed to other causes in a complex older patient.4
The absence of clear diagnostic algorithms or risk stratification tools specifically validated for older transplant recipients with suspected IgA nephritis recurrence further complicates timely and accurate diagnosis. This delay can lead to missed opportunities for early intervention, potentially allowing the disease to progress to a more advanced stage where treatment is less effective and associated with greater morbidity. The Oxford Handbook of Nephrology and Hypertension provides a comprehensive overview of renal disease, but even this authoritative text highlights the diagnostic complexities in specific patient populations.
Emerging Therapies and Their Relevance
Newer therapies for IgA nephritis, such as targeted-release budesonide (e.g., Nefecon), which delivers corticosteroids directly to the Peyer's patches in the gut to reduce IgA production, have shown promise in reducing proteinuria in native IgA nephritis. Clinical trials like the NefIgArd study demonstrated a significant reduction in proteinuria and stabilisation of eGFR. However, these trials primarily enrolled younger adults, with limited representation of older patients or those with recurrent disease post-transplant. The safety profile of these novel agents, particularly regarding their systemic immunosuppressive effects, needs careful evaluation in the elderly, who are more susceptible to infections and other complications.5
Other investigational agents targeting specific pathways in IgA nephritis, such as complement inhibitors or B-cell depleting agents, are also in various stages of development. While these therapies offer hope for more targeted and potentially safer treatment options, their applicability and safety in older, post-transplant patients with recurrent IgA nephritis remain largely unknown. The financial implications of these newer, often expensive, therapies also need consideration, especially in healthcare systems with limited resources.5
The Need for Dedicated Research
The current lack of evidence for managing IgA nephritis in older, post-transplant patients is a significant clinical unmet need. Future research must prioritise the inclusion of this vulnerable population in clinical trials. This requires careful trial design, considering appropriate endpoints that reflect graft survival and patient quality of life, alongside robust safety monitoring tailored to the unique risks of older individuals. Trials should also explore different dosing strategies and treatment durations, acknowledging potential pharmacokinetic and pharmacodynamic differences in the elderly.6
Observational studies and registries could also play a crucial role in gathering real-world data on treatment patterns, outcomes, and adverse events in older transplant recipients with recurrent IgA nephritis. Such data could help generate hypotheses for future interventional trials and inform clinical practice in the interim. Collaborative efforts across multiple transplant centres would be essential to accrue sufficient patient numbers for meaningful analysis.6
Where it Falls Short
The absence of dedicated, adequately powered trials in older transplant recipients means that clinicians are left to navigate complex treatment decisions with insufficient data. This often leads to a conservative approach, potentially undertreating aggressive recurrence, or conversely, overtreating with immunosuppression, leading to avoidable adverse events. The long-term impact on graft survival and patient morbidity and mortality remains an area of significant uncertainty. Without specific data, it is impossible to define optimal treatment algorithms or provide evidence-based recommendations for this growing patient group. The ethical imperative to include older patients in research, while ensuring their safety, is paramount. The current situation represents a significant disparity in care, where a substantial patient population is effectively excluded from the benefits of evidence-based medicine. This is not merely an academic point; it directly impacts patient outcomes and quality of life.
Clinicians managing older transplant recipients with recurrent IgA nephritis operate in a data vacuum. The absence of dedicated trials means treatment decisions are often a best guess, balancing the known risks of immunosuppression against the potential for graft loss. This is a precarious position, particularly given the increased comorbidity burden in this demographic.
The current reliance on extrapolated data from younger cohorts or native kidney disease is simply inadequate. Older patients exhibit different immune responses and drug pharmacokinetics, making a one-size-fits-all approach potentially harmful. We need to acknowledge that what works for a 40-year-old may not be appropriate for a 75-year-old with a transplanted kidney.
Until robust data emerges, individualised risk-benefit assessments are paramount. This involves meticulous monitoring for adverse events, careful dose adjustments, and open discussions with patients and their families about the uncertainties. The pharmaceutical industry and academic researchers must prioritise inclusive trial designs to address this critical evidence gap.
The lack of evidence also creates a disparity in access to newer, targeted therapies. While drugs like Nefecon show promise, their safety and efficacy in older, post-transplant patients are unknown. This leaves clinicians hesitant to prescribe, potentially denying a vulnerable group access to beneficial treatments, or exposing them to unquantified risks.
- The Pivot Current treatment guidelines for IgA nephritis recurrence post-transplant largely overlook the specific needs and risks of older patients.
- The Data There is a critical absence of dedicated clinical trials focusing on IgA nephritis in transplant recipients over 65, particularly regarding long-term outcomes.
- The Action Clinicians must individualise care for older post-transplant IgA nephritis patients, carefully weighing potential benefits against increased risks of adverse events, while advocating for more inclusive research.
ART-2026-1004
·07/26
Drafted with AI assistance, reviewed and approved by the editorial team. This publication is intended for healthcare professionals, researchers, and life science industry professionals. Content is provided for informational and educational purposes only and does not constitute medical advice.
Digital health and patient experience are my beat: the apps, the wearables, the real-world evidence claims, and whether any of it changes outcomes. Sceptical by training and optimistic by instinct.
Cite This Article
Ward S, Voss M. Iga nephritis in older transplant patients: a data desert for optimal care. The Life Science Feed. Published July 28, 2026. Updated July 28, 2026. Accessed July 28, 2026. https://thelifesciencefeed.com/nephrology/iga-nephropathy/research/iga-nephritis-in-older-transplant-patients-a-data-desert-for-optimal-care.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources: published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402-2414.
2. Kasiske BL, et al. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant. 2009;9 Suppl 3:S1-S155.
3. Floege J, et al. IgA nephropathy: a disease of the mucosal immune system. N Engl J Med. 2019;381(25):2465-2476.
4. Haas M, et al. IgA nephropathy: an update on diagnosis and treatment. Kidney Int. 2019;95(4):774-786.
5. Barratt J, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NefIgArd): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10380):1098-1111.
6. Pillebout E, et al. Recurrent IgA nephropathy after kidney transplantation. Kidney Int. 2015;88(2):217-226.
